Table 3.

Effects of adding ezetimibe to rosuvastatin or increasing rosuvastatin dosage on lipid and metabolic outcomes

	Values after 12 weeks		Change after 12 weeks		P Value (Difference Between add on vs. increased dose)
	Ezetimibe add-on group (n = 21)	Increased rosuvastatin (n = 18)	Ezetimibe add-on group (n = 21)	Increased rosuvastatin (n = 18)
ApoB, g/L	0.89 ± 0.25	0.88 ± 0.22	−0.17 ± 0.18*	−0.13 ± 0.25*	0.53
ApoA1, g/L	1.47 ± 0.26	1.56 ± 0.30	−0.07 ± 0.25	−0.05 ± 0.24	0.15
ApoB:ApoA1	0.55 ± 0.29	0.60 ± 0.23	−0.15 ± 0.29*	−0.12 ± 0.33	0.81
TC, mmol/L	4.23 ± 1.03	4.56 ± 0.75	−1.01 ± 0.79*	−0.50 ± 0.63*	0.03
LDL, mmol/L	2.12 ± 0.63	2.07 ± 0.46	−0.68 ± 0.54*	−0.48 ± 0.55*	0.37
HDL, mmol/L	1.21 ± 0.27	1.31 ± 0.48	−0.00 ± 0.29	0.03 ± 015	0.72
TC:HDL	3.29 ± 1.41	3.73 ± 0.92	−1.63 ± 2.86*	−0.52 ± 0.65*	0.09
TG, mmol/L	1.92 ± 0.98	2.88 ± 1.42	−0.62 ± 0.58*	−0.17 ± 0.57	0.03
AIP	0.16 ± 0.30	0.30 ± 0.38	−0.12 ± 0.20*	−0.03 ± 0.12	0.13
Non-HDL-C, mmol/L	3.06 ± 0.98	3.25 ± 0.71	−0.97 ± 0.68*	−0.53 ± 0.13	0.03
FBG, mmol/L	6.87 ± 2.49	5.82 ± 1.29	0.34 ± 1.28	−0.34 ± 1.75	0.15
hsCRP, mg/L	5.19 ± 7.25	1.72 ± 1.87	−0.60 ± 12.5	−1.06 ± 3.48	0.87
Creatinine, μmol/L	98 ± 58	151 ± 265	8 ± 48	53 ± 258	0.43
ALT, U/L	42 ± 22	34 ± 15	9 ± 17*	1.28 ± 16.6*	0.18
AST, U/L	32 ± 21	29 ± 8	4 ± 14	−0.10 ± 8	0.30
CK, U/L	126 ± 63	189 ± 103	−20 ± 90	12 ± 69	0.23

Data are given as mean (±SD)

*Significant change from their baseline (p < 0.05)

apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; API, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase